Related Experiment Video
Updated: Aug 4, 2025
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
1Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA, USA.
Pegcetacoplan, a novel C3 inhibitor, is FDA-approved for Paroxysmal Nocturnal Hemoglobinuria (PNH). This review covers its efficacy, safety, and clinical use in PNH patients.
Area of Science:
- Hematology
- Pharmacology
- Immunology
Background:
- Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare blood disorder.
- The complement system plays a key role in PNH pathogenesis.
- Current treatments aim to inhibit complement-mediated hemolysis.
Purpose of the Study:
- To review the efficacy and safety of Pegcetacoplan for PNH treatment.
- To discuss clinical considerations for using Pegcetacoplan in PNH patients.
Main Methods:
- Review of clinical trial data for Pegcetacoplan in PNH.
- Analysis of safety and efficacy endpoints from published studies.
Main Results:
- Pegcetacoplan demonstrated significant efficacy in PNH patients.
- The safety profile of Pegcetacoplan was evaluated in clinical trials.
Conclusions:
- Pegcetacoplan is an effective and approved therapy for PNH.
- Considerations for Pegcetacoplan use in PNH management are discussed.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...